We have developed a new approach to genomics that generates one number to define a patient’s condition across the entire genetic level, a "thermometer" for genetic health. This method produces results that can predict response to drug treatment months in advance of clinical assessments, improve the efficiency of the drug pipeline, and provide better ways to measure the true health of patients.
Only 8% of drug candidates currently make it through clinical trials to FDA approval, often at the cost of hundreds of millions of dollars. To improve on this process, a small but increasing number of companies now offer genetic biomarker services to pharmaceutical, biotech, and contract research organizations (CROs). The use of biomarkers in the pharmaceutical pipeline has now become an important part of the $20 billion biomarker industry. Within this burgeoning market, our company offers the capability of improved prediction, a wider breadth of biomarkers, and the ability to quickly develop biomarkers customized to the clients needs. Our company is the first company that truly offers Biomarkers as a Service (BaaS).
We are seeking $375K to build out our core staff and port our current processing platform to the cloud (Amazon EC2). We expect rapid growth in revenue as our services are utilized in the growing surrogate biomarker industry, leading to a high multiple acquisition in the 2-5 years time frame. Executive Summary and case studies available upon request.